到2030年,大多数欧洲国家将无法达到欧盟的抗菌药物使用目标:欧洲和经合组织国家的历史分析,社区和医院部门的比较以及到2040年的预测。

IF 3.1 4区 医学 Q2 PHARMACOLOGY & PHARMACY Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-08-01 Epub Date: 2025-02-17 DOI:10.1007/s00210-025-03887-5
Lilly Josephine Bindel, Roland Seifert
{"title":"到2030年,大多数欧洲国家将无法达到欧盟的抗菌药物使用目标:欧洲和经合组织国家的历史分析,社区和医院部门的比较以及到2040年的预测。","authors":"Lilly Josephine Bindel, Roland Seifert","doi":"10.1007/s00210-025-03887-5","DOIUrl":null,"url":null,"abstract":"<p><p>The rise of bacterial resistance threatens the treatment of infections and is closely linked to the consumption of antibacterial drugs. The EU's 'One Health' approach aims to address this issue by requiring Member States to reduce consumption by 20% by 2030. This study analyses antibacterial consumption trends in the total care of European and non-European OECD countries, compares the community and hospital sector, uses ARIMA modelling and correlation analysis to provide long-term forecasts, assesses patterns of consumption and evaluates whether current trends are in line with the EU target. Projections to 2040 show increases for Spain (+36.6%; 30.7 DID), Greece (+31.4%; 37.5 DID), Czechia (+29.7%; 19.4 DID), Bulgaria (+28.3%; 33. 7 DID), Malta (+26.5%; 28.8 DID), Denmark (+25.7%; 19.8 DID), Croatia (+17.4%; 24.9 DID), Italy (+13.7%; 26.3 DID), Germany (+7.6%; 12.6 DID), Australia (+12.4%, 18.2 DID), Canada (+8.0%, 14.8 DID), Chile (+90.1%, 66.7 DID), Costa Rica (+0.4%, 19.7 DID), Japan (+22.7%, 12.8 DID) and Korea (+24.3%, 31.9 DID). Declines are forecast for Belgium (-0.5%; 20.5 DID), Romania (-0.6%; 27.2 DID), Cyprus (-1.0%; 33.2 DID), Luxembourg (-2.2%; 19.8 DID), Norway (-3.4%; 15.1 DID), Latvia (-5.5%; 14.1 DID), Lithuania (-6.4%; 17.5 DID), the Netherlands (-8.4%; 8. 8 DID), Portugal (-10.6%; 16.1 DID), Estonia (-12.1%; 11.2 DID), Slovakia (-16.1%; 16.8 DID), France (-17.7%; 19.8 DID), Hungary (-20.4%; 11.3 DID), Slovenia (-21.9%; 10.5 DID), Finland (-24.8%; 9.7 DID), Iceland (-24.9%; 13.9 DID), Sweden (-30.4%; 7.0 DID) and Israel (-70.7%, 4.7 DID). A significant positive correlation was found between current versus projected consumption levels and changes, highlighting stable prescribing patterns in many countries. Northern and Central Europe maintain low levels of consumption with decreasing trends, whereas Latin America, Eastern and Southern Europe show higher levels with projected increases. Western Europe and Asia shows a mixed pattern, with varying trends of increase and decrease. Alarmingly, only Sweden is projected to meet the 20% reduction target by 2030. Even in the best-case scenario, only a proportion of European countries are projected to meet the target, including Austria, Belgium, Croatia, Cyprus, Finland, France, Greece, Hungary, Italy, Iceland, Lithuania, Luxembourg, Latvia, Portugal, Slovenia, Slovakia and Spain, while 11 countries show no potential for a successful reduction. The reliability of the projections is considered good to moderate. Divergent trends between the community and hospital sectors further complicate the assessment of progress and underline the need for targeted interventions. Current trends suggest that the EU targets are unlikely to be met, highlighting the urgent need to strengthen stewardship programmes. Further research is needed to address other objectives of the 'One Health' approach, including the use of classes of antibacterial drugs and the development of bacterial resistance.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":"10195-10220"},"PeriodicalIF":3.1000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12350445/pdf/","citationCount":"0","resultStr":"{\"title\":\"Most European countries will miss EU targets on antibacterial use by 2030: historical analysis of European and OECD countries, comparison of community and hospital sectors and forecast to 2040.\",\"authors\":\"Lilly Josephine Bindel, Roland Seifert\",\"doi\":\"10.1007/s00210-025-03887-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The rise of bacterial resistance threatens the treatment of infections and is closely linked to the consumption of antibacterial drugs. The EU's 'One Health' approach aims to address this issue by requiring Member States to reduce consumption by 20% by 2030. This study analyses antibacterial consumption trends in the total care of European and non-European OECD countries, compares the community and hospital sector, uses ARIMA modelling and correlation analysis to provide long-term forecasts, assesses patterns of consumption and evaluates whether current trends are in line with the EU target. Projections to 2040 show increases for Spain (+36.6%; 30.7 DID), Greece (+31.4%; 37.5 DID), Czechia (+29.7%; 19.4 DID), Bulgaria (+28.3%; 33. 7 DID), Malta (+26.5%; 28.8 DID), Denmark (+25.7%; 19.8 DID), Croatia (+17.4%; 24.9 DID), Italy (+13.7%; 26.3 DID), Germany (+7.6%; 12.6 DID), Australia (+12.4%, 18.2 DID), Canada (+8.0%, 14.8 DID), Chile (+90.1%, 66.7 DID), Costa Rica (+0.4%, 19.7 DID), Japan (+22.7%, 12.8 DID) and Korea (+24.3%, 31.9 DID). Declines are forecast for Belgium (-0.5%; 20.5 DID), Romania (-0.6%; 27.2 DID), Cyprus (-1.0%; 33.2 DID), Luxembourg (-2.2%; 19.8 DID), Norway (-3.4%; 15.1 DID), Latvia (-5.5%; 14.1 DID), Lithuania (-6.4%; 17.5 DID), the Netherlands (-8.4%; 8. 8 DID), Portugal (-10.6%; 16.1 DID), Estonia (-12.1%; 11.2 DID), Slovakia (-16.1%; 16.8 DID), France (-17.7%; 19.8 DID), Hungary (-20.4%; 11.3 DID), Slovenia (-21.9%; 10.5 DID), Finland (-24.8%; 9.7 DID), Iceland (-24.9%; 13.9 DID), Sweden (-30.4%; 7.0 DID) and Israel (-70.7%, 4.7 DID). A significant positive correlation was found between current versus projected consumption levels and changes, highlighting stable prescribing patterns in many countries. Northern and Central Europe maintain low levels of consumption with decreasing trends, whereas Latin America, Eastern and Southern Europe show higher levels with projected increases. Western Europe and Asia shows a mixed pattern, with varying trends of increase and decrease. Alarmingly, only Sweden is projected to meet the 20% reduction target by 2030. Even in the best-case scenario, only a proportion of European countries are projected to meet the target, including Austria, Belgium, Croatia, Cyprus, Finland, France, Greece, Hungary, Italy, Iceland, Lithuania, Luxembourg, Latvia, Portugal, Slovenia, Slovakia and Spain, while 11 countries show no potential for a successful reduction. The reliability of the projections is considered good to moderate. Divergent trends between the community and hospital sectors further complicate the assessment of progress and underline the need for targeted interventions. Current trends suggest that the EU targets are unlikely to be met, highlighting the urgent need to strengthen stewardship programmes. Further research is needed to address other objectives of the 'One Health' approach, including the use of classes of antibacterial drugs and the development of bacterial resistance.</p>\",\"PeriodicalId\":18876,\"journal\":{\"name\":\"Naunyn-Schmiedeberg's archives of pharmacology\",\"volume\":\" \",\"pages\":\"10195-10220\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12350445/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Naunyn-Schmiedeberg's archives of pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00210-025-03887-5\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Naunyn-Schmiedeberg's archives of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00210-025-03887-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

细菌耐药性的增加威胁到感染的治疗,并与抗菌药物的使用密切相关。欧盟的“同一个健康”方针旨在通过要求成员国到2030年将消费量减少20%来解决这一问题。本研究分析了欧洲和非欧洲经合组织国家总体护理中的抗菌药物消费趋势,比较了社区和医院部门,使用ARIMA建模和相关性分析提供长期预测,评估消费模式并评估当前趋势是否符合欧盟目标。到2040年的预测显示,西班牙将增长36.6%;30.7 DID),希腊(+31.4%;37.5 DID),捷克(+29.7%;19.4 DID),保加利亚(+28.3%;33. 7 DID),马耳他(+26.5%;28.8 DID),丹麦(+25.7%;19.8 DID),克罗地亚(+17.4%;24.9 DID),意大利(+13.7%;26.3 DID),德国(+7.6%;12.6 DID),澳大利亚(+12.4%,18.2 DID),加拿大(+8.0%,14.8 DID),智利(+90.1%,66.7 DID),哥斯达黎加(+0.4%,19.7 DID),日本(+22.7%,12.8 DID)和韩国(+24.3%,31.9 DID)。预计比利时将下降0.5%;20.5 DID),罗马尼亚(-0.6%;27.2 DID),塞浦路斯(-1.0%;33.2 DID),卢森堡(-2.2%;19.8 DID),挪威(-3.4%;15.1 DID),拉脱维亚(-5.5%;14.1 DID),立陶宛(-6.4%;17.5 DID),荷兰(-8.4%;8. 8 DID),葡萄牙(-10.6%;16.1 DID),爱沙尼亚(-12.1%;11.2 DID),斯洛伐克(-16.1%;16.8 DID),法国(-17.7%;19.8 DID),匈牙利(-20.4%;11.3 DID),斯洛文尼亚(-21.9%;10.5% DID),芬兰(-24.8%;9.7 DID),冰岛(-24.9%;13.9 DID),瑞典(-30.4%;7.0 DID)和以色列(-70.7%,4.7 DID)。目前与预计的消费水平和变化之间存在显著的正相关关系,突出表明许多国家的处方模式稳定。北欧和中欧的消费量保持在较低水平,并呈下降趋势,而拉丁美洲、东欧和南欧的消费量较高,预计会增加。西欧和亚洲呈现混合模式,增加和减少的趋势各不相同。令人担忧的是,预计到2030年,只有瑞典能实现减排20%的目标。即使在最好的情况下,预计也只有一部分欧洲国家能够达到目标,包括奥地利、比利时、克罗地亚、塞浦路斯、芬兰、法国、希腊、匈牙利、意大利、冰岛、立陶宛、卢森堡、拉脱维亚、葡萄牙、斯洛文尼亚、斯洛伐克和西班牙,另有11个国家没有成功减排的潜力。预测的可靠性被认为是良好到中等的。社区和医院部门之间的不同趋势进一步使进展评估复杂化,并强调需要有针对性的干预措施。目前的趋势表明,欧盟的目标不太可能实现,这凸显了加强管理计划的迫切需要。需要进一步研究以解决“同一个健康”方针的其他目标,包括各类抗菌药物的使用和细菌耐药性的发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Most European countries will miss EU targets on antibacterial use by 2030: historical analysis of European and OECD countries, comparison of community and hospital sectors and forecast to 2040.

The rise of bacterial resistance threatens the treatment of infections and is closely linked to the consumption of antibacterial drugs. The EU's 'One Health' approach aims to address this issue by requiring Member States to reduce consumption by 20% by 2030. This study analyses antibacterial consumption trends in the total care of European and non-European OECD countries, compares the community and hospital sector, uses ARIMA modelling and correlation analysis to provide long-term forecasts, assesses patterns of consumption and evaluates whether current trends are in line with the EU target. Projections to 2040 show increases for Spain (+36.6%; 30.7 DID), Greece (+31.4%; 37.5 DID), Czechia (+29.7%; 19.4 DID), Bulgaria (+28.3%; 33. 7 DID), Malta (+26.5%; 28.8 DID), Denmark (+25.7%; 19.8 DID), Croatia (+17.4%; 24.9 DID), Italy (+13.7%; 26.3 DID), Germany (+7.6%; 12.6 DID), Australia (+12.4%, 18.2 DID), Canada (+8.0%, 14.8 DID), Chile (+90.1%, 66.7 DID), Costa Rica (+0.4%, 19.7 DID), Japan (+22.7%, 12.8 DID) and Korea (+24.3%, 31.9 DID). Declines are forecast for Belgium (-0.5%; 20.5 DID), Romania (-0.6%; 27.2 DID), Cyprus (-1.0%; 33.2 DID), Luxembourg (-2.2%; 19.8 DID), Norway (-3.4%; 15.1 DID), Latvia (-5.5%; 14.1 DID), Lithuania (-6.4%; 17.5 DID), the Netherlands (-8.4%; 8. 8 DID), Portugal (-10.6%; 16.1 DID), Estonia (-12.1%; 11.2 DID), Slovakia (-16.1%; 16.8 DID), France (-17.7%; 19.8 DID), Hungary (-20.4%; 11.3 DID), Slovenia (-21.9%; 10.5 DID), Finland (-24.8%; 9.7 DID), Iceland (-24.9%; 13.9 DID), Sweden (-30.4%; 7.0 DID) and Israel (-70.7%, 4.7 DID). A significant positive correlation was found between current versus projected consumption levels and changes, highlighting stable prescribing patterns in many countries. Northern and Central Europe maintain low levels of consumption with decreasing trends, whereas Latin America, Eastern and Southern Europe show higher levels with projected increases. Western Europe and Asia shows a mixed pattern, with varying trends of increase and decrease. Alarmingly, only Sweden is projected to meet the 20% reduction target by 2030. Even in the best-case scenario, only a proportion of European countries are projected to meet the target, including Austria, Belgium, Croatia, Cyprus, Finland, France, Greece, Hungary, Italy, Iceland, Lithuania, Luxembourg, Latvia, Portugal, Slovenia, Slovakia and Spain, while 11 countries show no potential for a successful reduction. The reliability of the projections is considered good to moderate. Divergent trends between the community and hospital sectors further complicate the assessment of progress and underline the need for targeted interventions. Current trends suggest that the EU targets are unlikely to be met, highlighting the urgent need to strengthen stewardship programmes. Further research is needed to address other objectives of the 'One Health' approach, including the use of classes of antibacterial drugs and the development of bacterial resistance.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.20
自引率
5.60%
发文量
142
审稿时长
4-8 weeks
期刊介绍: Naunyn-Schmiedeberg''s Archives of Pharmacology was founded in 1873 by B. Naunyn, O. Schmiedeberg and E. Klebs as Archiv für experimentelle Pathologie und Pharmakologie, is the offical journal of the German Society of Experimental and Clinical Pharmacology and Toxicology (Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, DGPT) and the Sphingolipid Club. The journal publishes invited reviews, original articles, short communications and meeting reports and appears monthly. Naunyn-Schmiedeberg''s Archives of Pharmacology welcomes manuscripts for consideration of publication that report new and significant information on drug action and toxicity of chemical compounds. Thus, its scope covers all fields of experimental and clinical pharmacology as well as toxicology and includes studies in the fields of neuropharmacology and cardiovascular pharmacology as well as those describing drug actions at the cellular, biochemical and molecular levels. Moreover, submission of clinical trials with healthy volunteers or patients is encouraged. Short communications provide a means for rapid publication of significant findings of current interest that represent a conceptual advance in the field.
期刊最新文献
Comparative extracellular and intracellular anti-Mycobacterium tuberculosis activity of three tanshinones from Salvia miltiorrhiza and oral cryptotanshinone efficacy in mice. Assessment of methylene blue and NAD on LPS-induced acute brain injury: effects on neuroinflammation, oxidative stress, and blood-brain barrier integrity in a rat endotoxemia model. Molecular mechanisms underlaying fluoride-induced neurotoxicity: interplay of antioxidants and endoplasmic reticulum stress-mediated apoptotic pathways in rats. Edaravone dexborneol in acute ischemic stroke: a systematic review and meta-analysis of randomized trials with clinical and thrombectomy-specific subgroup analyses. Integrating network pharmacology, molecular docking, machine learning, and experimental validation: puerarin improves sepsis-induced acute kidney injury via the Sirt1-Nrf2-HO-1 pathway.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1